Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03350919 · ClinicalTrials.gov registry record · NA

Visual Restoration for Hemianopia

A NA study of Hemianopia and Quadrantanopia, sponsored by University of Rochester.

Completed
Registry status
NA
Development phase
48
Enrollment target
3
Study locations

NCT03350919 is a NA study of Hemianopia and Quadrantanopia that has completed, run by University of Rochester. The registered enrollment target is 48 participants, below the 138-participant average among 6 other Hemianopia trials with a reported enrollment target (65% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03350919, a NA study of Hemianopia and Quadrantanopia, has completed, sponsored by University of Rochester.

COMPLETED
Registry status
NA
Development phase
48 participants
Enrollment target
3
Study locations

Study Summary

The purpose of this research is to assess the efficacy of a visual training task on reducing the size of a visual field deficit caused by brain damage in adults, and its ability to improve visual functions in this patient population.

Interventions

  • DEVICE Training in the blind field
  • DEVICE Training in the intact field

Study Locations (3)

Florida

  • Bascom Palmer Eye Institute, University of Miami Health Services - Miami

New York

  • Flaum Eye Institute, University of Rochester Medical Center - Rochester

Pennsylvania

  • Scheie Eye Institute - Philadelphia

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2018-03-15
Est. Completion 2019-12-03
Phase NA

Sponsor

University of Rochester

636 total trials

What the Registry Record Tells You About NCT03350919

The ClinicalTrials.gov registry entry for NCT03350919 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 138-participant average among 6 other Hemianopia trials with a reported enrollment target (65% lower). The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Hemianopia appearing as the primary indexed condition, and to 2 interventions - of which Training in the blind field is the first listed.

NCT03350919 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Florida, New York, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT03350919 about?

NCT03350919 is a clinical study titled "Visual Restoration for Hemianopia". The purpose of this research is to assess the efficacy of a visual training task on reducing the size of a visual field deficit caused by brain damage in adults, and its ability to improve visual functions in this patient population.

What is the current status of trial NCT03350919?

This trial is currently completed. It is a NA study. The enrollment target is 48 participants. The study started on 2018-03-15. Estimated completion is 2019-12-03.

What conditions does trial NCT03350919 study?

This clinical trial studies the following conditions: Hemianopia, Quadrantanopia, Stroke Induced Vision Loss.

What interventions are being tested in trial NCT03350919?

The interventions under investigation include: Training in the blind field (DEVICE), Training in the intact field (DEVICE).

Who is sponsoring clinical trial NCT03350919?

This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03350919 being conducted?

This trial has 3 study locations across Florida, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hemianopia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.